11.12.13
Primus Pharmaceuticals, Scottsdale, AZ has introduced a new prescription medical food, Fosteum PLUS, featuring Oslo, Norway-based NattoPharma’s MenaQ7 Crystals. The companies report that this is the first medical food product to incorporate vitamin K2, targeting bone health while protecting cardiovascular health. Launched in the U.S. in 2012, this introduction marks MenaQ7’s first inclusion in the prescription therapeutic drug medical market.
Fosteum PLUS is for the clinical dietary management of the metabolic processes associated with osteopenia and osteoporosis with MenaQ7 vitamin K2 for improved bone results and cardiac safety. Fosteum Plus can only be used with a physician’s prescription.
Eric Anderson, global vice president of marketing for NattoPharma stated, “Fosteum PLUS represents a ground-breaking development for bone health, as the inclusion of ultra-high purity; patented MenaQ7 is based on the unique three-year study, published in Osteoporosis International, which demonstrates MenaQ7’s clear preservation of bone constitution and strength in menopausal women.”
Fosteum PLUS is for the clinical dietary management of the metabolic processes associated with osteopenia and osteoporosis with MenaQ7 vitamin K2 for improved bone results and cardiac safety. Fosteum Plus can only be used with a physician’s prescription.
Eric Anderson, global vice president of marketing for NattoPharma stated, “Fosteum PLUS represents a ground-breaking development for bone health, as the inclusion of ultra-high purity; patented MenaQ7 is based on the unique three-year study, published in Osteoporosis International, which demonstrates MenaQ7’s clear preservation of bone constitution and strength in menopausal women.”